The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors.
 
Filippo G. De Braud
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD; Novartis; Philogen; SERVIER
 
Jean-Pascal H. Machiels
Consulting or Advisory Role - Boehringer Ingelheim; Merck Sharp & Dohme; Pfizer
Research Funding - Bayer; Janssen; Novartis; Sanofi
 
Marcello Tiseo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pierre Fabre
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Sylvie Rottey
No Relationships to Disclose
 
Matteo Duca
No Relationships to Disclose
 
Marie Laruelle
Travel, Accommodations, Expenses - Biotest
 
Stefania Salvagni
No Relationships to Disclose
 
Lore Lapeire
No Relationships to Disclose
 
Laura Manfreda
Employment - Boehringer Ingelheim
 
Céline Veau
Employment - Boehringer Ingelheim
 
Daniela Fischer
Employment - Boehringer Ingelheim
 
Mahmoud Ould-Kaci
Employment - Boehringer Ingelheim